A Risk-Benefit Assessment of Slow-Acting Antirheumatic Drugs in Rheumatoid Arthritis
- 1 July 1994
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 11 (1) , 21-36
- https://doi.org/10.2165/00002018-199411010-00004
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- VARIATIONS AMONG RHEUMATOLOGISTS IN PRESCRIBING AND MONITORING OF DISEASE MODIFYING ANTIRHEUMATOID DRUGSRheumatology, 1992
- Successful Treatment of Gold-induced Aplastic Anaemia with Granulocyte Macrophage Colony Stimulating FactorRheumatology, 1992
- Lipogranulomas and Gold in the Liver in Rheumatoid ArthritisThe American Journal of Surgical Pathology, 1992
- COMPLEMENT C4 NULL ALLELES AS A MARKER OF GOLD OR D-PENICILLAMINE TOXICITY IN THE TREATMENT OF RHEUMATOID ARTHRITISRheumatology, 1992
- Penicillamine in Rheumatoid ArthritisDrug Safety, 1992
- The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty‐five years of diseaseArthritis & Rheumatism, 1991
- Autoantibodies in d-penicillamine-induced myasthenia gravis: A comparison with idiopathic myasthenia and rheumatoid arthritisClinical Immunology and Immunopathology, 1991
- Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritisThe Journal of Pediatrics, 1990
- Ophthalmologic safety of long‐term hydroxychloroquine treatmentArthritis & Rheumatism, 1979
- Neutropenia associated with chrysotherapy for juvenile rheumatoid arthritisThe Journal of Pediatrics, 1978